Authors
Latest:
Scordo on Model-Based ATG Dosing in Allo-HCTMichael Scordo, MD, discusses the implications of a new approach to dosing antithymocyte globulin in patients undergoing an allogeneic hematopoietic stem cell transplant.
Latest:
Lenvatinib Plus Pembrolizumab Shows Activity in Kidney CancerLenvatinib plus pembrolizumab showed activity and a favorable safety profile in nonmetastatic clear cell renal cell carcinoma, per phase 2 study results.
Latest:
Academic Perspectives on the Evolving Treatment Landscape in MPNsAn expert shares their perspective on the future of care for patients with myeloproliferative neoplasms (MPNs).
Latest:
CheckMate 649 Study in GI Cancers Shows Survival Benefit for Nivolumab/ChemotherapyJaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.
Latest:
Phase I/II Study Demonstrates Good Efficacy for Gastric CancerShuichi Hironaka, MD, PhD, discusses the efficacy of a phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line treatment of patients with advanced gastric cancer during the 2020 Gastrointestinal Cancers Symposium.
Latest:
AI Tools for Accurate Cancer Diagnosis and Tailored TreatmentAnil Parwani, MD, PhD, discusses how he sees artificial intelligence technology contributing to personalized medicine and helping to tailor treatment plans for individual patients in the future.
Latest:
Achieving Health Equity in Liver CancerPrimary liver cancer death rates vary by region, and much is still to be done in the area of health equity.
Latest:
Biomarkers Employed in CheckMate 739 for Patients With MPMSolange Peters, MD, PhD, discusses the biomarkers for immunotherapy used in the phase 3 CheckMate 743 trial.
Latest:
Best Therapies for HER2+ Breast Cancer Are Also Best for Brain MetastasesThomas Bachelot, MD, PhD, discusses therapies available for patients with HER2-positive breast cancer and brain metastases.
Latest:
Beyond the Doctor: How Remote Pharmacists are Revolutionizing Cancer CareAndrea Roman, PharmD, BCOP, discusses findings from a study investigating the benefits of remote oncology pharmacists.
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
Toripalimab Combo Delivers Long-Term Efficacy in Nasopharyngeal CancerDeborah Wong, MD, PhD, discusses the toripalimab combination that is now considered standard of care in nasopharyngeal cancer.
Latest:
Olanzapine May Help Manage AEs From Tyrosine Kinase InhibitorsOlanzapine may help manage adverse effects from tyrosine kinase inhibitors, though further randomized, placebo-controlled studies are needed to confirm these findings.
Latest:
Advancing Cancer Care: NYU Langone’s Molecular Oncology ProgramAlec Kimmelman, MD, PhD, and Shridar Ganesan, MD, PhD, discuss the institution's new molecular oncology program.
Latest:
Cancer Research Across Continents: Fujiwara’s Path From Japan to the USIn this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Latest:
COVID-19 and Its Impact on Oncology Clinical TrialsCoronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.
Latest:
Novel Combination Therapy Impresses With Safety/Efficacy in DLBCLChristopher J. Melani, MD, discusses updated data from the phase 1b/2 ViPOR trial of the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, in patients with diffuse large B-cell lymphoma.
Latest:
Low Receipt of ACR-Recommended Follow-Care Discovered Among Patients With Lung CancerAccording to a prospective study of lung cancer screening examinations conducted over a 5-year period, there is low adherence to guidelines recommending follow-up radiologic imaging or diagnostic procedures in patient with lung cancer.
Latest:
Treatment Approaches for Early-Stage Lung CancerPatrick Forde, MBBCh offers an overview of current standard-of-care treatments as well as emerging immunotherapy options for treating early-stage, resectable non-small cell lung cancer.
Latest:
Osimertinib Proves Frontline Status in EGFR+ Advanced NSCLCJonathan W. Goldman, MD, discusses the use of osimertinib in the first line setting for patients with non–small cell lung cancer.
Latest:
Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium StudyResults from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.
Latest:
Assessing the Need for Extended Monitoring After Axi-Cel InfusionOlalekan O Oluwole, MD, MBBS, discusses the background and rationale of the research he contributed to, which was presented at the 2025 Transplantation & Cellular Therapy Meetings.
Latest:
Closing Remarks on Bispecific AntibodiesJustin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.
Latest:
Pancreatic Cancer Awareness Month: Novel Targeted Therapy in PDACThe landscape for patients with pancreatic ductal adenocarcinoma has shifted due to novel targeted therapies that are opening new options for patients.
Latest:
Treating the Patient With CML Who Is Pregnant or Trying to Become PregnantCareful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Latest:
Methods and Design of the QUILT 3032 Study in NMIBCSam S. Chang, MD, MBA, discusses the methods and design of the QUILT 3032 study.
Latest:
First- and Later-Line Therapies in Patients With GISTDomenech Asbun, MD, discusses first-, second-, and later lines of therapy for patients with gastrointestinal stromal tumor.
Latest:
Important Biomarkers for Cervical and Ovarian CancersJohn Diaz, discusses key targets for cervical cancer and ovarian cancer.
Latest:
DRd Shows Longer Time-to-Next-Treatment vs VRd in MyelomaDoris Hansen, MD, discusses the efficacy of daratumumab, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone in newly diagnosed myeloma.
